Advances in mRNA‐Lipid Nanoparticle Engineering for Immune Cell Targeting and Immune Modulation

Sep 17, 2025Small methods

Improving mRNA-Lipid Nanoparticles to Target Immune Cells and Change Immune Responses

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Lipid nanoparticles (LNPs) encapsulating messenger RNA (mRNA) may enhance targeted immune cell delivery.

mRNA-based platforms enable in vivo synthesis of proteins that have natural modifications, which can improve their effectiveness and lower the likelihood of immune reactions.
Naked mRNA has limitations such as instability and poor uptake by cells, which can hinder its clinical use.
LNPs can protect mRNA and facilitate its efficient delivery to specific target cells.
Recent advancements indicate that mRNA-LNPs can specifically alter immune cell functions, potentially improving the precision of immunotherapy.
Strategies for enhancing delivery efficiency and immunological responses are being explored to support the clinical application of mRNA-LNP immunotherapies.

AI simplified

Immunotherapy has transformed therapeutic paradigms, especially in oncology, by leveraging antibodies, cytokines, and cell-based strategies. In recent years, immunotherapy has expanded its impact to combat a broad spectrum of diseases, including fibrotic, autoimmune, and infectious disorders. Messenger RNA (mRNA)-based platforms offer distinct advantages for immunotherapy by enabling in vivo synthesis of proteins with native post-translational modifications to enhance bioactivity and reduce immunogenicity. mRNA also allows non-viral, transient reprogramming of immune cells in vivo, supporting scalable manufacturing and eliminating the risk of insertional mutagenesis. However, naked mRNA faces clinical limitations including inherent instability, poor cellular uptake, and non-targeted delivery. Lipid nanoparticles (LNPs) can overcome these challenges by encapsulating mRNA for protected and efficient delivery to target cells. Importantly, recent advances have demonstrated the potential of mRNA-LNPs to modulate immune cell function with cell-type specificity, enhancing therapeutic precision. This review highlights progress in engineering mRNA-LNPs for targeted immune cell delivery, strategies for immune cell-specific modulation, and applications across immune-related pathologies. Design considerations to improve delivery efficiency and immunological outcomes are also discussed, supporting the clinical translation of mRNA-LNP immunotherapies.

Full Text

Full text is available at the source.

View full text ↗

Advances in mRNA‐Lipid Nanoparticle Engineering for Immune Cell Targeting and Immune Modulation

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief